The AstraZeneca Rollercoaster Dips Again

AstraZeneca said it will release up-to-date results within 48 hours after being stung last night by an independent US monitoring panel’s concerns that the company had relied on “outdated information” in the promising analysis of its COVID-19 vaccine’s efficacy data.
The NIAID panel flagged the issue in an unusual late-night statement that was thin on details.

The questions could delay AstraZeneca’s hopes for a speedy FDA approval. 

“The last thing this vaccine needs is more concern when we kind of thought we were at that point now where we’d put to bed all the other concerns,” says Paul Griffin, of the University of Queensland in Brisbane.

Comments +


Post a Comment

Restricted HTML

  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Back to top